Skip to main content
SpringerLink
Log in

Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles’ Heel?

  • Chapter
Breast Cancer Chemosensitivity

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 608))

Abstract

Deregulation of the G1 cyclin, cyclin E, has been shown to be both the most powerful predictor of prognosis in early stage breast cancer as well as a significant determinant of tumor aggressiveness.1,2 It may also contribute to treatment failure due to chemoresistance. Because some form of cell cycle deregulation is present in all malignant cells,3 increasing understanding of these processes is starting to provide new opportunities to overcome the cells’ resistance mechanisms.

One particular form of cyclin E deregulation, the generation of hyperactive low molecular weight isoforms, is especially intriguing. Because only tumor cells contain the machinery necessary to generate these isoforms,4 they not only provide a mechanism of targeting critical cell cycle events, but their presence may also provide both a means of increased specificity for targeting malignant cells, as well as an objective measure of response.

This review describes the mechanisms of resistance to commonly used systemic therapies for the treatment of breast cancer, with particular respect to the role of the cell cycle. The mechanisms and effects of the deregulation of cyclin E in breast cancer are reviewed and novel approaches to circumventing chemoresistance through abrogation of the malignant cell cycle are proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Keyomarsi K, O’Leary N, Molnar G et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54(2):380–385.

    PubMed  CAS  Google Scholar 

  2. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347(20):1566–1575.

    Article  PubMed  CAS  Google Scholar 

  3. Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246(4930):603–608.

    Article  PubMed  CAS  Google Scholar 

  4. Porter DC, Zhang N, Danes C et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001; 21(18):6254–6269.

    Article  PubMed  CAS  Google Scholar 

  5. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351(9114):1451–1467.

    Article  Google Scholar 

  6. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352(9132):930–942.

    Article  Google Scholar 

  7. Berns K, Hijmans EM, Bernards R. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene 1997; 15(11):1347–1356.

    Article  PubMed  CAS  Google Scholar 

  8. Berns K, Martins C, Dannenberg JH et al. p27kip1-independent cell cycle regulation by MYC. Oncogene 2000; 19(42):4822–4827.

    Article  PubMed  CAS  Google Scholar 

  9. Beier R, Burgin A, Kiermaier A et al. Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. Embo J 2000; 19(21):5813–5823.

    Article  PubMed  CAS  Google Scholar 

  10. Roussel MF, Theodoras AM, Pagano M et al. Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci USA 1995; 92(15):6837–6841.

    Article  PubMed  CAS  Google Scholar 

  11. Leone G, DeGregori J, Sears R et al. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997; 387(6631):422–426.

    Article  PubMed  CAS  Google Scholar 

  12. Santoni-Rugiu E, Falck J, Mailand N et al. Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 2000; 20(10):3497–3509.

    Article  PubMed  CAS  Google Scholar 

  13. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996; 8(6):805–814.

    CAS  Google Scholar 

  14. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13(12):1501–1512.

    Article  PubMed  CAS  Google Scholar 

  15. Muller-Tidow C, Metzger R, Kugler K et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage nonsmall cell lung cancer. Cancer Res 2001; 61(2):647–653.

    PubMed  CAS  Google Scholar 

  16. Porter PL, Malone KE, Heagerty PJ et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3(2):222–225.

    Article  PubMed  CAS  Google Scholar 

  17. Richter J, Wagner U, Konomen J et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000; 157(3):787–794.

    PubMed  CAS  Google Scholar 

  18. Sui L, Dong Y, Ohno M et al. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001; 83(1):56–63.

    Article  PubMed  CAS  Google Scholar 

  19. Gros P, Ben Neriah YB, Croop JM et al. Isolation and expression of a complementary DNA that confers multidrug resitance. Nature 1986; 323(6090):728–731.

    Article  PubMed  CAS  Google Scholar 

  20. Koike K, Kawabe T, Tanaka T et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57(24):5475–5479.

    PubMed  CAS  Google Scholar 

  21. Cole SP, Chanda ER, Dicke FP et al. Non P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991; 51(13):3345–3352./

    PubMed  CAS  Google Scholar 

  22. DeVore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: Effects on enzyme-mediated DNA clevage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res 1992; 52(8):2156–2161.

    PubMed  CAS  Google Scholar 

  23. Takano H, Kohno K, Ono M et al. Increased phosphorylation of DNA topisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 1991; 51(15):3951–3957.

    PubMed  CAS  Google Scholar 

  24. Feldhoff PW, Mirski SE, Cole SP et al. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994; 54(3):756–762.

    PubMed  CAS  Google Scholar 

  25. Mirski SE, Cole SP. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug resistant human lung cancer cell line. Cancer Res 1995; 55(10):2129–2134.

    PubMed  CAS  Google Scholar 

  26. Harker WG, Slade DL, Parr RL et al. Sclective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res 1995; 55(21):4962–4971.

    PubMed  CAS  Google Scholar 

  27. Wessel I, Jensen PB, Falck J et al. Loss of amino acids 1490 Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha inhuman small cell lung cencer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res 1997; 57(20):4451–4454.

    PubMed  CAS  Google Scholar 

  28. Rubin E, Halt W. Anthracyclines and DNA Intercalators/Epipodophyllotoxins/Camptothecins/DNA Topoisomerases. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol. 1. Hamilton: BC Decker, 2003:783.

    Google Scholar 

  29. Fenselau C, Kan MN, Rao SS et al. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res 1977; 37(8 Pt 1):2538–2543.

    PubMed  CAS  Google Scholar 

  30. Colvin M. Alkylating agents and platinum antitumor compounds. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol. 1. Hamilton: BC Decker, 2003:762.

    Google Scholar 

  31. Colvin M, Russo JE, Hilton J et al. Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues. Adv Enzyme Regul 1988; 27:211–221.

    Article  PubMed  CAS  Google Scholar 

  32. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984; 44(11):5156–5160.

    PubMed  CAS  Google Scholar 

  33. Koelling TM, Yeager AM, Hilton J et al. Development and characterization of a cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis x Brown Norway hybrid rat. Blood 1990; 76(6):1209–1213.

    PubMed  CAS  Google Scholar 

  34. Parsons PG, Lean J, Kable EP et al. Relationship between resistanace to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines. Biochem Pharmacol 1990; 40(12):2641–2649.

    Article  PubMed  CAS  Google Scholar 

  35. Rekha GK, Sreerama L, Sladek NE. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem Pharmacol 1994; 48(10):1943–1952.

    Article  PubMed  CAS  Google Scholar 

  36. Sreerama L, Sladek NE. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res 1994; 54(8):2176–2185.

    PubMed  CAS  Google Scholar 

  37. Buller AL, Clapper ML, Tew KD. Glutathione S-transferase in nitrogen mustard-resistant and-sensitive cell lines. Mol Pharmacol 1987; 31(6):575–578.

    PubMed  CAS  Google Scholar 

  38. Nakagawa K, Saijo N, Tsuchida S et al. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem 1990; 265(8):4296–4301.

    PubMed  CAS  Google Scholar 

  39. Pallante SL, Lisek CA, Dulik DM et al. Glutathione conjugates. Immobilized enzyme synthesis and characterization by fast atom bombardment mass spectrometry. Drug Metab Dispos 1986; 1493):313–318.

    PubMed  CAS  Google Scholar 

  40. Puchalski RB, Fahl WE. Expression of recombinant glutathione Sptransferase pi, Ya, or Yb1 confers resistance to alkylating agents. Proc Natl Acd Sci USA 1990; 87(7):2443–2447.

    Article  CAS  Google Scholar 

  41. Tew KD, Bomber AM, Hoffman SJ. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 1988; 48(13):3622–3625.

    PubMed  CAS  Google Scholar 

  42. O’Connor PM, Ferris DK, White GA et al. Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ 1992; 3(1):43–52.

    PubMed  Google Scholar 

  43. Mulkins MA, Heidelberger C. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 1982; 42(3):965–973.

    PubMed  CAS  Google Scholar 

  44. Mulkins MA, Heidelberger C. Isolation of fluoropyrimidine-resistant murine leukemic cell lines by one-step mutation and selection. Cancer Res 1982; 42(3):956–964.

    PubMed  CAS  Google Scholar 

  45. Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 1984; 25(2):303–309.

    PubMed  CAS  Google Scholar 

  46. Houghton JA, Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in exnografts of human colorectal adenocarcinoma. Eur J Cancer Clin Oncol 1983; 19(6):807–815.

    Article  PubMed  CAS  Google Scholar 

  47. Kufe DW, Major PP, Egan EM et al. 5-Fluoro-2′-deoxyuridine incorporation in L1210 DNA. J Biol Chem 1981; 256(17):8885–8888.

    PubMed  CAS  Google Scholar 

  48. Ingraham HA, Tseng BY, Goulian M. Mechanism for exclusion of 5-fluorouracil from DNA. Cancer Res 1980; 40(4):998–1001.

    PubMed  CAS  Google Scholar 

  49. Morikawa K, Fan D, Denkins YM et al. Mechanisms of combined effects of gamma-interferon and 5-fluorouracil on human colon cancers implanted into nude mice. Cancer Res 1989; 49(4):799–805.

    PubMed  CAS  Google Scholar 

  50. Jiang W, Lu Z, He Y et al. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997; 3(3):395–399.

    PubMed  CAS  Google Scholar 

  51. Etienne MC, Cheradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13(7):1663–1670.

    PubMed  CAS  Google Scholar 

  52. Bapat AR, Zarow C, Danenberg PV. Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J Biol Chem 1983; 258(7):4130–4136.

    PubMed  CAS  Google Scholar 

  53. Berger SH, Jenh CH, Johnson LF et al. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985; 28(5):461–467.

    PubMed  CAS  Google Scholar 

  54. Aschele C, Sobrero A, Faderan MA et al. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52(7):1855–1864.

    PubMed  CAS  Google Scholar 

  55. Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem Pharmacol 1995; 49(4):559–565.

    Article  PubMed  CAS  Google Scholar 

  56. Sobrero AF, Aschele C, Guglielmi AP et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993; 85(23):1937–1944.

    Article  PubMed  CAS  Google Scholar 

  57. Pizzorno G, Diasio R, Cheng Y. Pyrimidine and Purine Antimetabolites. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol. 1. Hamilton: BC Decker, 2003:748.

    Google Scholar 

  58. Curt GA, Jolivet J, Carney DN et al. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin Invest 1985; 76(4):1323–1329.

    Article  PubMed  CAS  Google Scholar 

  59. Li WW, Waltham M, Tong W et al. Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: A novel mechanism of intrinsic resistance to methotrexate (MTX). Adv Exp Med Biol 1993; 338:635–638.

    PubMed  CAS  Google Scholar 

  60. Longo GS, Gorlick R, Tong WP et al. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood 1997; 90(3):1241–1245.

    PubMed  CAS  Google Scholar 

  61. Li WW, Lin JT, Tong WP et al. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 1992; 52(6):1434–1438.

    PubMed  CAS  Google Scholar 

  62. Longo GS, Gorlick R, Tong WP et al. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res 1997; 9(5):259–263.

    PubMed  CAS  Google Scholar 

  63. Guo W, Healey JH, Meyers PA et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5(3):621–627.

    PubMed  CAS  Google Scholar 

  64. Zhao R, Assaraf YG, Goldman ID. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 1998; 273(30):19065–19071.

    Article  PubMed  CAS  Google Scholar 

  65. Li W, Fan J, Hochhauser D et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995; 92(22):10436–10440.

    Article  PubMed  CAS  Google Scholar 

  66. Li W, Fan J, Banerjee D et al. Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 1999; 55(6):1088–1093.

    PubMed  CAS  Google Scholar 

  67. Fan J, Bertino JR. Functional roles of E2F in cell cycle regulation. Oncogene 1997; 14(10):1191–1200.

    Article  PubMed  CAS  Google Scholar 

  68. Alt FW, Kellems RE, Bertino JR et al. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells 1978. Biotechnology 1992; 24:397–410.

    PubMed  CAS  Google Scholar 

  69. Carman MD, Schornagel JH, Rivest RS et al. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 1984; 2(1):16–20.

    PubMed  CAS  Google Scholar 

  70. Cowan KH, Goldsmith ME, Levine RM et al. Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem 1982; 257(24):15079–15086.

    PubMed  CAS  Google Scholar 

  71. Curt GA, Carney DN, Cowan KH et al. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 1983; 308(4):199–202.

    PubMed  CAS  Google Scholar 

  72. Fischer GA. Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells. Biochem Pharmacol 1961; 7:75–77.

    Article  PubMed  CAS  Google Scholar 

  73. Horns Jr RC, Dower WJ, Schimke RT. Gene amplification in a leukemic patient treated with methotrexate. J Clin Oncol 1984; 2(1):2–7.

    PubMed  Google Scholar 

  74. Srimatkandada S, Medina WD, Cashmore AR et al. Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexate. Biochemistry 1983; 22(25):5774–5781.

    Article  PubMed  CAS  Google Scholar 

  75. Dedhar S, Hartley D, Fitz-Gibbons D et al. Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients. J Clin Oncol 1985; 3(11):1545–1552.

    PubMed  CAS  Google Scholar 

  76. Domin BA, Cheng YC, Hakala MT. Properties of dihydrofolate reductase from a methotrexate-resistant subline of human KB cells and comparison with enzyme from KB parent cells and mouse S180 AT/3000 cells. Mol Pharmacol 1982; 21(1):231–238.

    PubMed  CAS  Google Scholar 

  77. Flintoff WF, Essani K. Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry 1980; 19(18):4321–4327.

    Article  PubMed  CAS  Google Scholar 

  78. Goldie JH, Dedhar S, Krystal G. Properties of a methotrexate-insensitive variant of dihydrofolate reductase derived from methotrexate-resistant L5178Y cells. J Biol Chem 1981; 256(22):11629–11635.

    PubMed  CAS  Google Scholar 

  79. Melera PW, Davide JP, Oen H. Antifolate-resistant Chinese hamster cells. Molecular basis for the biochemical and structural heterogeneity among dihydrofolate reductases produced by drug-sensitive and drug-resistant cell lines. J Biol Chem 1988; 263(4):1978–1990.

    PubMed  CAS  Google Scholar 

  80. Gorlick R, Goker E, Trippett T et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89(3):1013–1018.

    PubMed  CAS  Google Scholar 

  81. Rowinsky E. Microtubule-targeting natural products. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:799.

    Google Scholar 

  82. Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90(20):9552–9556.

    Article  PubMed  CAS  Google Scholar 

  83. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17(3):1061–1070.

    PubMed  CAS  Google Scholar 

  84. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998; 58(16):3620–3626.

    PubMed  CAS  Google Scholar 

  85. Wang LG, Liu XM, Kreis W et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999; 44(5):355–361.

    Article  PubMed  CAS  Google Scholar 

  86. Huisman C, Ferreira CG, Broker LE et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the nonsmall cell lung cancer cell line NCI-H460. Clin Cancer Res 2002; 8(2):596–606.

    PubMed  CAS  Google Scholar 

  87. Horwitz SB, Cohen D, Rao S et al. Taxol: Mechanisms of action and resistance. J Natl Cancer Inst Monorg 1993; (15):55–61.

    Google Scholar 

  88. Cabral F, Wible L, Brenner S et al. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983; 97(1):30–39.

    Article  PubMed  CAS  Google Scholar 

  89. Cabral FR. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 1983; 97(1):22–29.

    Article  PubMed  CAS  Google Scholar 

  90. Kavallaris M, Kuo DY, Burkhart CA et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100(5):1282–1293.

    Article  PubMed  CAS  Google Scholar 

  91. Nicoletti MI, Valoti G, Giannakakou P et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: Correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001; 7(9):2912–2922.

    PubMed  CAS  Google Scholar 

  92. Ranganathan S, Benetatos CA, Colarusso PJ et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998; 77(4):562–566.

    PubMed  CAS  Google Scholar 

  93. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987; 47(24) Pt 1): 6517–6521.

    PubMed  CAS  Google Scholar 

  94. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992; 7(8):1587–1594.

    PubMed  CAS  Google Scholar 

  95. Murphy LJ, Murphy LC, Friesen HG. Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrinology 1987; 120(5):1882–1888.

    Article  PubMed  CAS  Google Scholar 

  96. Prall OW, Sarcevic B, Musgrove EA et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997; 272(16):10882–10894.

    Article  PubMed  CAS  Google Scholar 

  97. Altucci L, Addeo R, Cicatiello L et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996; 12(11):2315–2324.

    PubMed  CAS  Google Scholar 

  98. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997; 17(7):4059–4069.

    PubMed  CAS  Google Scholar 

  99. Prall OW, Carroll JS, Sutherland RL. A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2. J Biol Chem 2001; 276(48):45433–45442.

    Article  PubMed  CAS  Google Scholar 

  100. Osborne CK, Shou J, Massarweh S et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11(2 Pt 2):865s–870s.

    PubMed  CAS  Google Scholar 

  101. Razandi M, Alton G, Pedram A et al. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 2003; 23(5):1633–1646.

    Article  PubMed  CAS  Google Scholar 

  102. McKenna NJ, Lanz RB, O’Malley BW. Nuclear receptor coregulator: Cellular and molecular biology. Endocr Rev 1999; 20(3):321–344.

    Article  PubMed  CAS  Google Scholar 

  103. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 2000; 18(17):3172–3186.

    PubMed  CAS  Google Scholar 

  104. Parker MG. Steroid and related receptors. Curr Opin Cell Biol 1993; 5(3):499–504.

    Article  PubMed  CAS  Google Scholar 

  105. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96(12):926–935.

    Article  PubMed  CAS  Google Scholar 

  106. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270(5241):1491–1494.

    Article  PubMed  CAS  Google Scholar 

  107. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000; 20(14):5041–5047.

    Article  PubMed  CAS  Google Scholar 

  108. Nicholson RI, McClelland RA, Robertson JF et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6(3):373–387.

    Article  PubMed  CAS  Google Scholar 

  109. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95(5):353–361.

    PubMed  CAS  Google Scholar 

  110. Smith CL, Nawaz Z, O’Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997; 11(6):657–666.

    Article  PubMed  CAS  Google Scholar 

  111. Buzdar A, Harvey H. Aromatase Inhibitors. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003;947.

    Google Scholar 

  112. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19(18):3808–3816.

    PubMed  CAS  Google Scholar 

  113. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365(9453):60–62.

    Article  PubMed  CAS  Google Scholar 

  114. Buzdar A, Harvey H. Aromatase Inhibitors. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:957.

    Google Scholar 

  115. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000; 19(53):6115–6121.

    Article  PubMed  CAS  Google Scholar 

  116. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6(2):117–127.

    Article  PubMed  CAS  Google Scholar 

  117. Dieras V, Fumoleau P, Romieu G et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22(24):4958–4965.

    Article  PubMed  CAS  Google Scholar 

  118. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17(11):3412–3417.

    PubMed  CAS  Google Scholar 

  119. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14(9):1391–1398.

    Article  PubMed  CAS  Google Scholar 

  120. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18(22):3758–3767.

    PubMed  CAS  Google Scholar 

  121. Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am J Clin Oncol 2003; 26(3):317–322.

    Article  PubMed  CAS  Google Scholar 

  122. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21(11):2101–2109.

    Article  PubMed  CAS  Google Scholar 

  123. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12(11):1527–1532.

    Article  PubMed  CAS  Google Scholar 

  124. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18(22):3748–3757.

    PubMed  CAS  Google Scholar 

  125. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3):719–726.

    Article  PubMed  CAS  Google Scholar 

  126. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992; 61:441–470.

    Article  PubMed  CAS  Google Scholar 

  127. Hartwell LH, Weinert TA. Checkpoints: Controls that ensure the order of cell cycle events. Science 1989; 246(4930):629–634.

    Article  PubMed  CAS  Google Scholar 

  128. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974; 71(4):1286–1290.

    Article  PubMed  CAS  Google Scholar 

  129. Evans T, Rosenthal ET, Youngblom J et al. Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 1983; 33(2):389–396.

    Article  PubMed  CAS  Google Scholar 

  130. Pines J. Cyclins: Wheels within wheels. Cell Growth Differ 1991; 2(6):305–310.

    PubMed  CAS  Google Scholar 

  131. Ohtsubo M, Theodoras AM, Schumacher J et al. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15(5):2612–2624.

    PubMed  CAS  Google Scholar 

  132. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 1997; 3:171–191.

    PubMed  CAS  Google Scholar 

  133. Zhang HS, Gavin M, Dahiya A et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000; 101(1):79–89.

    Article  PubMed  CAS  Google Scholar 

  134. Montagnoli A, Fiore F, Eytan E et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13(9):1181–1189.

    Article  PubMed  CAS  Google Scholar 

  135. Perez-Roger I, Kim SH, Griffiths B et al. Cyclins D1 and D2 mediate myc-induced proliferation via sequenstration of p27(Kip10 and p21(Cip1). Embo J 1999; 18(19):5310–5320.

    Article  PubMed  CAS  Google Scholar 

  136. Alevizopoulos K, Vlach J, Hennecke S et al. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. Embo J 1997; 16(17):5322–5333.

    Article  PubMed  CAS  Google Scholar 

  137. Cassia R, Moreno-Bueno G, Rodriguez-Perales S et al. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003; 201(4):589–595.

    Article  PubMed  CAS  Google Scholar 

  138. Schraml P, Bucher C, Bissig H et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003; 200(3):375–382.

    Article  PubMed  CAS  Google Scholar 

  139. Strohmaier H, Spruck CH, Kaiser P et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413(6853):316–322.

    Article  PubMed  CAS  Google Scholar 

  140. Rajagopalan H, Jallepalli PV, Rago C et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428(6978):77–81.

    Article  PubMed  CAS  Google Scholar 

  141. Bloom J, Pagano M. Deregulated degradation of the edk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13(1):41–47.

    Article  PubMed  CAS  Google Scholar 

  142. Koepp DM, Schaefer LK, Ye X et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001; 294(5540):173–177.

    Article  PubMed  CAS  Google Scholar 

  143. Harwell RM, Porter DC, Danes C et al. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000; 60(2):481–489.

    PubMed  CAS  Google Scholar 

  144. Akli S, Zheng PJ, Multani AS et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004; 64(9):3198–3208.

    Article  PubMed  CAS  Google Scholar 

  145. Furstenthal L, Kaiser BK, Swanson C et al. Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication. J Cell Biol 2001; 152(6):1267–1278.

    Article  PubMed  CAS  Google Scholar 

  146. Ma T, Van Tine BA, Wei Y et al. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 2000; 14(18):2298–2313.

    Article  PubMed  CAS  Google Scholar 

  147. Zhao J, Kennedy BK, Lawrence BD et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev 2000; 14(18):2283–2297.

    Article  PubMed  CAS  Google Scholar 

  148. Fisk HA, Winey M. The mouse Mps1p-like kinase regulates centrosome duplication. Cell 2001; 106(1):95–104.

    Article  PubMed  CAS  Google Scholar 

  149. Okuda M, Horn HF, Tarapore P et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103(1):127–140.

    Article  PubMed  CAS  Google Scholar 

  150. Shanahan F, Seghezzi W, Parry D et al. Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol Cell Biol 1999; 19(2):1460–1469.

    PubMed  CAS  Google Scholar 

  151. Wang C, Chua K, Seghezzi W et al. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev 1998; 12(10):1409–1414.

    Article  PubMed  CAS  Google Scholar 

  152. Seghezzi W, Chua K, Shanahan F et al. Cyclin E associates with components of the premRNA splicing machinery in mammalian cells. Mol Cell Biol 1998; 18(8):4526–4536.

    PubMed  CAS  Google Scholar 

  153. Hara E, Hall M, Peters G. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. Embo J 1997; 16(2):332–342.

    Article  PubMed  CAS  Google Scholar 

  154. Deed RW, Hara E, Atherton GT et al. Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation. Mol Cell Biol 1997; 17(12):6815–6821.

    PubMed  CAS  Google Scholar 

  155. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993; 259(5103):1908–1912.

    Article  PubMed  CAS  Google Scholar 

  156. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2003; 2 (4 Suppl 1):S38–47.

    Google Scholar 

  157. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002; 4(3):95–99.

    Article  PubMed  CAS  Google Scholar 

  158. Carlson BA, Dubay MM, Sausville EA et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56(13):2973–2978.

    PubMed  CAS  Google Scholar 

  159. Losiewicz MD, Carlson BA, Kaur G et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994; 201(2):589–595.

    Article  PubMed  CAS  Google Scholar 

  160. Gray NS, Wodicka L, Thunnissen AM et al. Exploiting chemical libraries, structure, and genomics in the search for kinase in hibitors. Science 1998; 281(5376):533–538.

    Article  PubMed  CAS  Google Scholar 

  161. Senderowicz AM, Headlee D, Stinson SF et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16(9):2986–2999.

    PubMed  CAS  Google Scholar 

  162. Thomas JP, Tutsch KD, Cleary JF et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002; 50(6):465–472.

    Article  PubMed  CAS  Google Scholar 

  163. Schiller JH, Harrington D, Belani CP. et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002; 346(2):92–98.

    Article  PubMed  CAS  Google Scholar 

  164. Shapiro GI, Supko JG, Patterson A et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV nonsmall cell lung cancer. Clin Cancer Res 2001; 7(6):1590–1599.

    PubMed  CAS  Google Scholar 

  165. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: A randomized trial. Jama 2003; 290(16):2149–2158.

    Article  PubMed  CAS  Google Scholar 

  166. Meijer L, Borgne A, Mulner O et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243(1–2):527–536.

    Article  PubMed  CAS  Google Scholar 

  167. McClue SJ, Blake D, Clarke R et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102(5):463–468.

    Article  PubMed  CAS  Google Scholar 

  168. Benson C, White J, Twelves C et al. A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.

    Google Scholar 

  169. Pierga J, Faiver S, Vera K. A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.

    Google Scholar 

  170. Kim KS, Kimball SD, Misra RN et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 2002; 45(18):3905–3927.

    Article  PubMed  CAS  Google Scholar 

  171. Shapiro G, Lewis N, Bai S et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.

    Google Scholar 

  172. McCormick J, Gadgeel M, Helmke W et al. Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.

    Google Scholar 

  173. Jones S, Burris H, Kies M et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Chicago: Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.

    Google Scholar 

  174. Akinaga S, Nomura K, Gomi K et al. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol 1994; 33(4):273–280.

    Article  PubMed  CAS  Google Scholar 

  175. Akiyama T, Yoshida T, Tsujita T et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997; 57(8):1495–1501.

    PubMed  CAS  Google Scholar 

  176. Akiyama T, Shimizu M, Okabe M et al. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole. Anticancer Drugs 1999; 10(1):67–78.

    Article  PubMed  CAS  Google Scholar 

  177. Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 1999; 18(41):5691–5702.

    Article  CAS  Google Scholar 

  178. Kawakami K, Futami H, Takahara J et al. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1999; 219(3):778–783.

    Article  Google Scholar 

  179. Seynaeve CM, Stetler-Stevenson M, Sebers S et al. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993; 53(9):2081–2086.

    PubMed  CAS  Google Scholar 

  180. Shimizu E, Zhao MR, Nakanishi H et al. Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. Oncology 1996; 53(6):494–504.

    Article  PubMed  CAS  Google Scholar 

  181. Usuda J, Saijo N, Fukuoka K et al. Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells. Int J Cancer 2000; 85(2):275–280.

    PubMed  CAS  Google Scholar 

  182. Wang Q, Fan S, Eastman A et al. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996; 88(14):956–965.

    Article  PubMed  CAS  Google Scholar 

  183. Busby EC, Leistritz DF, Abraham RT et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60(8):2108–2112.

    PubMed  CAS  Google Scholar 

  184. Graves PR, Yu L, Schwarz JK et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275(8):5600–5605.

    Article  PubMed  CAS  Google Scholar 

  185. Sarkaria JN, Busby EC, Tibbetts RS et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999; 59(17):4375–4382.

    PubMed  CAS  Google Scholar 

  186. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002; 21(11):1727–1738.

    Article  PubMed  CAS  Google Scholar 

  187. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98(20):10983–10985.

    Article  PubMed  CAS  Google Scholar 

  188. Sausville EA, Arbuck SG, Messmann R et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19(8):2319–2333.

    PubMed  CAS  Google Scholar 

  189. Senderowicz A, Headlee D, Lush R et al. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Amsterdam, Holland: Paper presented at: 10th National Cancer Institute-European Organization fro Research on Treatment of Cancer Symposium, 1998.

    Google Scholar 

  190. Shao RG, Cao CX, Shimizu T et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57(18):4029–4035.

    PubMed  CAS  Google Scholar 

  191. Jones CB, Clements MK, Wasi S et al. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: Abrogation of S/G(2) arrest. Cancer Chemother Pharmacol 2000; 45(3):252–258.

    Article  PubMed  CAS  Google Scholar 

  192. Hsueh CT, Kelsen D, Schwartz GK. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 1998; 4(9):2201–2206.

    PubMed  CAS  Google Scholar 

  193. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996; 2(5):791–797.

    PubMed  CAS  Google Scholar 

  194. Garcia HH, Brar GA, Nguyen DH et al. Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. J Biol Chem 2005; 280(10):8756–8764.

    Article  PubMed  CAS  Google Scholar 

  195. Chen X, Danes C, Lowe M et al. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst 2000; 92(17):1403–1413.

    Article  PubMed  CAS  Google Scholar 

  196. Barboule N, Chadebech P, Baldin V et al. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 1997; 15(23):2867–2875.

    Article  PubMed  CAS  Google Scholar 

  197. Yu D, Jing T, Liu B et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998; 2(5):581–591.

    Article  PubMed  CAS  Google Scholar 

  198. Bacus SS, Yarden Y, Oren M et al. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 1996; 12(12):2535–2547.

    PubMed  CAS  Google Scholar 

  199. Sugiyama K, Shimizu M, Akiyama T et al. Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro. Br J Cancer 1998; 77(11):1737–1743.

    PubMed  CAS  Google Scholar 

  200. Rao S, Porter DC, Chen X et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc natl Acad Sci USA 1999; 96(14):7797–7802.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgical Oncology and Experimental Radiation Oncology at University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, 77030, USA

    Laura Lambert & Khandan Keyomarsi

Authors
  1. Laura Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khandan Keyomarsi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Khandan Keyomarsi .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Dihua Yu

  2. Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Mien-Chie Hung

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Lambert, L., Keyomarsi, K. (2007). Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles’ Heel?. In: Yu, D., Hung, MC. (eds) Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology, vol 608. Springer, New York, NY. https://doi.org/10.1007/978-0-387-74039-3_4

Download citation

Publish with us

Policies and ethics

Search

Navigation